In vivo biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer

Marco Danova, Katia Bencardino, Mariangela Manzoni, Donatella Grasso, Sara Mariucci, Bianca Rovati

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: No exhaustive data are available on the in vivo biological effects of pegfilgrastim utilized in dose-dense chemotherapy (CT). The cytokinetic effects exerted in a multicyclic CT program by this cytokine on CD34+/38+ peripheral blood (PB) progenitor cells was the focus of this study. Patients and Methods: PB samples from 19 breast cancer patients treated with 4 courses of docetaxel and epirubicin followed by pegfilgrastim were studied. The absolute number of CD34+/38+ circulating progenitor cells (CPCs) along with the percentage undergoing G0/G1, S and G2-M phases of the cell cycle or showing apoptotic features, were evaluated at baseline, after the first and before the fourth CT course using a dedicated flow cytometric technique. Results and Conclusion: Pegfilgrastim, after CT, exerted stimulatory effects on the cell cycle status of PB CD34+/38+ CPCs, at the same time protecting them from apoptosis. This was particularly evident 7 days after administration and tended to decrease one week later, without additional cytokinetic changes during the subsequent CT courses.

Original languageEnglish
Pages (from-to)3399-3402
Number of pages4
JournalAnticancer Research
Volume27
Issue number5 A
Publication statusPublished - Sep 2007

Fingerprint

Breast Neoplasms
Drug Therapy
Stem Cells
docetaxel
Cell Cycle
Epirubicin
G2 Phase
Cell Division
Blood Cells
pegfilgrastim
Apoptosis
Cytokines

Keywords

  • Cell kinetics
  • Chemotherapy
  • Docetaxel
  • Epirubicin
  • Pegfilgrastim

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

In vivo biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer. / Danova, Marco; Bencardino, Katia; Manzoni, Mariangela; Grasso, Donatella; Mariucci, Sara; Rovati, Bianca.

In: Anticancer Research, Vol. 27, No. 5 A, 09.2007, p. 3399-3402.

Research output: Contribution to journalArticle

@article{142abc72e1084d1883cf5c3582449eb9,
title = "In vivo biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer",
abstract = "Background: No exhaustive data are available on the in vivo biological effects of pegfilgrastim utilized in dose-dense chemotherapy (CT). The cytokinetic effects exerted in a multicyclic CT program by this cytokine on CD34+/38+ peripheral blood (PB) progenitor cells was the focus of this study. Patients and Methods: PB samples from 19 breast cancer patients treated with 4 courses of docetaxel and epirubicin followed by pegfilgrastim were studied. The absolute number of CD34+/38+ circulating progenitor cells (CPCs) along with the percentage undergoing G0/G1, S and G2-M phases of the cell cycle or showing apoptotic features, were evaluated at baseline, after the first and before the fourth CT course using a dedicated flow cytometric technique. Results and Conclusion: Pegfilgrastim, after CT, exerted stimulatory effects on the cell cycle status of PB CD34+/38+ CPCs, at the same time protecting them from apoptosis. This was particularly evident 7 days after administration and tended to decrease one week later, without additional cytokinetic changes during the subsequent CT courses.",
keywords = "Cell kinetics, Chemotherapy, Docetaxel, Epirubicin, Pegfilgrastim",
author = "Marco Danova and Katia Bencardino and Mariangela Manzoni and Donatella Grasso and Sara Mariucci and Bianca Rovati",
year = "2007",
month = "9",
language = "English",
volume = "27",
pages = "3399--3402",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 A",

}

TY - JOUR

T1 - In vivo biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer

AU - Danova, Marco

AU - Bencardino, Katia

AU - Manzoni, Mariangela

AU - Grasso, Donatella

AU - Mariucci, Sara

AU - Rovati, Bianca

PY - 2007/9

Y1 - 2007/9

N2 - Background: No exhaustive data are available on the in vivo biological effects of pegfilgrastim utilized in dose-dense chemotherapy (CT). The cytokinetic effects exerted in a multicyclic CT program by this cytokine on CD34+/38+ peripheral blood (PB) progenitor cells was the focus of this study. Patients and Methods: PB samples from 19 breast cancer patients treated with 4 courses of docetaxel and epirubicin followed by pegfilgrastim were studied. The absolute number of CD34+/38+ circulating progenitor cells (CPCs) along with the percentage undergoing G0/G1, S and G2-M phases of the cell cycle or showing apoptotic features, were evaluated at baseline, after the first and before the fourth CT course using a dedicated flow cytometric technique. Results and Conclusion: Pegfilgrastim, after CT, exerted stimulatory effects on the cell cycle status of PB CD34+/38+ CPCs, at the same time protecting them from apoptosis. This was particularly evident 7 days after administration and tended to decrease one week later, without additional cytokinetic changes during the subsequent CT courses.

AB - Background: No exhaustive data are available on the in vivo biological effects of pegfilgrastim utilized in dose-dense chemotherapy (CT). The cytokinetic effects exerted in a multicyclic CT program by this cytokine on CD34+/38+ peripheral blood (PB) progenitor cells was the focus of this study. Patients and Methods: PB samples from 19 breast cancer patients treated with 4 courses of docetaxel and epirubicin followed by pegfilgrastim were studied. The absolute number of CD34+/38+ circulating progenitor cells (CPCs) along with the percentage undergoing G0/G1, S and G2-M phases of the cell cycle or showing apoptotic features, were evaluated at baseline, after the first and before the fourth CT course using a dedicated flow cytometric technique. Results and Conclusion: Pegfilgrastim, after CT, exerted stimulatory effects on the cell cycle status of PB CD34+/38+ CPCs, at the same time protecting them from apoptosis. This was particularly evident 7 days after administration and tended to decrease one week later, without additional cytokinetic changes during the subsequent CT courses.

KW - Cell kinetics

KW - Chemotherapy

KW - Docetaxel

KW - Epirubicin

KW - Pegfilgrastim

UR - http://www.scopus.com/inward/record.url?scp=35348945335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348945335&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 3399

EP - 3402

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 A

ER -